ACE and Hypertension: Recently, Zhang et al31 studied the ‘Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalised with COVID-19’ and concluded that inpatient use of ACEIs/ARBs was associated with a lower risk of all-cause mortality compared with ACEIs/ARBs non-users.